BEIJING, July 25, 2007 (PRIME NEWSWIRE) -- Lotus Pharmaceuticals, Inc. (OTCBB:LTUS) released its catalog of drugs, both currently on the market and those in development for future release. Annual projected sales, from the spotlighted drugs alone, would exceed $50 million.
From his Beijing offices, Dr. Liu Zhongyi, Lotus CEO and founder, explained: "Lotus markets both drugs developed through our R&D program and licensed drugs that have proved successful internationally. While not a complete catalog listing, some of these are:
Drugs developed by Lotus presently on the Chinese market:
1. Valsartan Capsules for the treatment of medium and critical degree
high blood pressure and coronary heart disease, with annual sales
estimated at $12 million.
2. Levofloxacin lactate for injection for the treatment of infectious
diseases, with annual sales estimated at $8 million.
3. Brimonidine tartrate eye drops for the treatment of glaucoma and
ocular hypertension, with annual sales estimated at $4 million.
4. Nicergoline for injection for the treatment of cerebrovascular
disease sequela and other peripheral circulation, with annual
sales estimated at $4 million.
Drugs under license to Lotus presently on the Chinese market:
1. Sodium Aescinate for injection for the treatment of cerebral
oedema caused by different diseases, trauma, swelling caused by
operation and venous return disturbance, with annual sales
estimated at $8 million.
2. Gatifioxacin for injection for the treatment of various infectious
diseases, with annual sales estimated at $6 million.
Drugs under development by Lotus not yet on the Chinese market:
1. Valsartan Dropping Pills, a patented medicine exclusively produced
by our company for the treatment of medium and critical degree
essential hypertension, with forecasted annual sales of $20
million.
"Lotus boasts of some of the finest and most modern facilities in the pharmaceutical industry in China. In addition, our 15 retail stores offer a complete pharmacy, while some even have gymnasiums and wellness spas. We cordially invite interested parties to tour our Beijing facilities and stores," concluded Dr. Liu.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. ("Lotus") owns and operates Liang Fang Pharmaceutical, Ltd. ("Liang") and En Zhe Jia Shi Pharmaceutical, Ltd. ("En Zhe"), two Chinese pharmaceutical companies located in Beijing. Liang and En Zhe form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liang and/or En Zhe (together, "Lotus East"), and a large number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters and a warehouse of 1,000 square meters. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.